Anabolic Agents and the Body: The Pharmacology of Performance, Without Myths - Episode 6: Anabolic Agents and the Cardiovascular System

When people discuss the effects of anabolic agents, attention almost automatically goes to muscle mass, strength and body composition. The cardiovascular system receives much less attention, even though some of the most important physiological consequences of androgen exposure are found here. The heart, blood vessels, lipid profile, blood pressure and circulating blood are part of one interconnected network, and changing one component can alter the demand placed on the others.

Cardiovascular risk associated with anabolic-androgenic steroid exposure is not a single adverse effect and cannot be evaluated correctly through one laboratory value, one blood-pressure reading, or a feeling of well-being. It can involve elevated blood pressure, unfavorable lipoprotein changes, increased hematocrit, endothelial dysfunction, cardiac remodeling and, in some individuals, serious cardiovascular events. That accumulation is what makes the subject essential to any serious discussion of performance pharmacology.

1. Why the Cardiovascular System Is a Major Target

The cardiovascular system must deliver blood and oxygen to tissues while maintaining perfusion pressure within a range compatible with organ function. The heart generates cardiac output, blood vessels regulate systemic resistance, the kidneys and hormonal systems participate in pressure and volume control, and blood itself influences flow properties. Anabolic-androgenic exposure can affect several of these levels at the same time.

This is why there is no single cardiovascular mechanism of anabolic steroids. One compound or exposure pattern may alter lipids, another may increase fluid and sodium retention and blood pressure, and another may strongly stimulate erythropoiesis. In practice, these effects can overlap, and the final risk reflects their combination and the individual's characteristics.

2. Blood Pressure: The First Signal You Should Not Ignore

Blood pressure reflects the interaction between cardiac output and systemic vascular resistance. When arterial pressure remains elevated, the heart and vessels are exposed to greater mechanical stress. Anabolic-androgenic exposure may contribute to higher blood pressure through multiple pathways, including effects on fluid balance, vascular function and neurohormonal regulation.

A practical problem is that hypertension can remain asymptomatic for a long time. An athlete can feel excellent during training and still have repeatedly elevated blood pressure. In cardiovascular physiology, absence of symptoms does not mean absence of biological stress.

Heart rate and blood pressure must also be interpreted in context. A relatively low resting heart rate in a trained athlete does not cancel out elevated blood pressure. Likewise, one normal reading does not exclude a problem if repeated measurements are high.

3. Cholesterol and Lipoproteins: The Invisible Part of the Risk

One of the most important changes associated with anabolic-androgenic exposure is an altered lipid profile. Depending on the compound, dose and route of administration, HDL cholesterol may fall and LDL cholesterol or other atherogenic particles may rise. This profile can promote atherosclerosis, the process through which lipids and inflammation contribute to plaque formation and progression within the arterial wall.

For the athlete, the problem is that lipid deterioration may occur without any visible decline in physical condition. A person can become more muscular, stronger and leaner while the biomarkers associated with atherosclerotic risk move in an unfavorable direction. The mirror cannot measure LDL, HDL or endothelial function.

When discussing lipids, it is also important to distinguish total cholesterol from its individual fractions. Cardiovascular risk cannot be summarized by a single number, and proper assessment should consider the full lipid profile and the other risk factors.

4. Erythrocytosis and Hematocrit: When Blood Becomes More Difficult to Manage

Androgens can stimulate erythropoiesis, increasing hemoglobin and hematocrit. An increase in red-cell mass can matter for oxygen transport, but excess is not automatically a cardiovascular advantage. As hematocrit rises, blood viscosity can also increase, changing circulatory dynamics.

This is one reason a complete blood count is relevant in people exposed to androgens. A high hematocrit can occur while an athlete feels completely normal. Risk is not assessed through the sensation of energy, but through objective measurement and clinical interpretation.

5. The Endothelium: The Inner Surface of Blood Vessels That Senses Change

The endothelium is the cellular layer lining blood vessels. It actively participates in vascular tone, inflammation, coagulation and the interaction between blood and the vessel wall. Under healthy conditions, the endothelium helps maintain functional vascular surfaces and regulates dilation and constriction.

Excess androgen exposure has been associated in medical literature with changes in vascular function and a less favorable cardiovascular environment. These changes can be difficult for an athlete to perceive directly, but they may contribute to cumulative risk over time.

6. The Heart Is Not Simply a Muscle That Becomes Bigger

One of the most persistent confusions in strength sports is the idea that any enlarged heart is automatically a better-performing heart. Training produces physiological cardiac adaptations, but pathological hypertrophy and remodeling driven by hemodynamic and hormonal stress are not equivalent to healthy athletic adaptation.

Anabolic-androgenic steroid exposure has been associated with ventricular hypertrophy, changes in diastolic function and other structural or functional cardiac abnormalities. The same overall increase in size can hide very different mechanisms. A heart adapted to training and a heart remodeled under chronic hemodynamic and hormonal stress should not be treated as equivalent simply because both can be described using the word "hypertrophy".

Over time, increased myocardial stiffness or impaired relaxation can compromise ventricular filling. For a strength athlete who already generates very high blood pressures during maximal efforts, that context becomes particularly important.

7. From Biomarker Changes to Cardiovascular Events

The purpose of discussing biomarkers is to understand what they may mean in reality. Elevated blood pressure, low HDL, high LDL or an increased hematocrit are not cardiovascular events by themselves. They are risk factors or intermediates that can contribute to a more dangerous cardiovascular environment.

When several of these changes occur together, the probability of an adverse outcome may increase. Clinical literature has associated anabolic-androgenic steroid use with a spectrum of cardiovascular problems including hypertension, atherogenic lipid changes, thrombosis and alterations in cardiac structure and function. Severity and reversibility vary, and individual risk cannot be inferred from a single marker.

8. Not All Anabolic Agents Have the Same Cardiovascular Profile

It is a mistake to treat all anabolic steroids as though they have identical cardiovascular effects. Chemical structure, androgenic activity, aromatization, pharmaceutical form, dose, duration and combinations can all alter the profile.

For example, 17-alpha-alkylation used by some oral steroids can produce particularly unfavorable lipid effects, while other agents may produce a different pattern. Aromatizable substances can add a different endocrine context, and combinations can amplify several mechanisms at once. Labels such as "mild" or "hard" are therefore not enough to assess cardiovascular risk.

9. Strongman and the Combination of Training Stress and Pharmacology

Strongman already carries its own cardiovascular stress. Events with very heavy loads, carries, medleys and repeated efforts can generate substantial acute cardiovascular responses. Introducing androgen exposure that can alter blood pressure, lipids, hematocrit or cardiac structure is therefore not an isolated variable.

External appearance can also mask risk. A large, conditioned athlete capable of tolerating enormous workloads can have exceptional functional capacity and, at the same time, cardiovascular risk factors that are not visible.

10. What Should Be Monitored Objectively

A responsible assessment is not based on impressions. Depending on the clinical context, a physician may consider repeated blood-pressure measurements, a complete blood count including hemoglobin and hematocrit, a lipid profile and other relevant markers. When indicated, cardiac assessment may include electrocardiography and echocardiography, with additional testing based on symptoms, medical history and findings.

The value of monitoring is not in collecting endless tests. It is in identifying meaningful trends and detecting changes before they become clinical events.

11. The Myth That "If Blood Pressure Is Good, the Heart Is Good"

Healthy blood pressure is important, but it does not mean cardiovascular risk is zero. Lipids, hematocrit, family history, smoking, sleep, sleep apnea, kidney function, body mass and other variables can substantially change the overall picture.

Likewise, an apparently normal echocardiogram at one point cannot erase other risk factors or retrospectively turn pharmacological exposure into a risk-free state. Cardiovascular risk is dynamic.

12. What Can Improve After Stopping Exposure?

Some cardiovascular changes associated with androgen exposure may improve after reducing or stopping exposure, but reversibility is not identical for every effect and cannot be guaranteed for every person. Some lipid or blood-pressure abnormalities may improve, while cardiac remodeling or atherosclerotic disease may require medical evaluation and treatment.

That distinction matters: "a marker returned to normal" is not the same as "cardiovascular risk disappeared." Biology does not have an instant reset button.

Conclusion: The Heart Does Not Negotiate With the Mirror

Anabolic agents can affect the cardiovascular system through several pathways at once. They can raise blood pressure, worsen the lipid profile, stimulate erythropoiesis, affect vascular function and contribute to structural and functional cardiac remodeling. For the strength athlete, these changes matter even more because they overlap with the cardiovascular stress already generated by extreme resistance exercise.

The central myth is that visible performance reflects cardiovascular health. It does not. Strength, muscle mass, visible vascularity and the ability to finish an event cannot tell you whether blood pressure is chronically elevated, HDL has fallen, hematocrit has risen or the heart has begun to remodel.

Performance pharmacology becomes mature only when the desired advantage and the biological cost are analyzed together. In the cardiovascular system, that cost can remain silent for years and become visible only when the available options are fewer.

References

Baggish, A. L., Weiner, R. B., Kanayama, G., Hudson, J. I., Lu, M. T., Hoffmann, U., & Pope, H. G. Jr. (2017). Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation.

Nieschlag, E., & Vorona, E. (2015). Medical consequences of doping with anabolic androgenic steroids: effects on reproductive and cardiovascular systems. European Journal of Endocrinology.

Baggish, A. L., Weiner, R. B., Kanayama, G., et al. (2020). Long-Term Anabolic-Androgenic Steroid Use Is Associated With Left Ventricular Dysfunction. Circulation: Heart Failure.

Nieschlag, E., & Behre, H. M. Testosterone: Action, Deficiency, Substitution. Springer.

Endotext. Androgen Physiology and cardiovascular considerations related to androgen exposure. NCBI Bookshelf.